Liquidia (NASDAQ:LQDA) Given “Buy” Rating at Needham & Company LLC

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research report issued on Monday, Benzinga reports. They presently have a $28.00 price objective on the stock. Needham & Company LLC’s target price suggests a potential upside of 82.05% from the company’s previous close.

Several other research firms have also commented on LQDA. Bank of America lifted their price target on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. HC Wainwright lifted their price target on Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. Wedbush reaffirmed an “underperform” rating and set a $3.00 price target on shares of Liquidia in a research report on Thursday, December 21st. Finally, LADENBURG THALM/SH SH lifted their price target on Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Liquidia Stock Up 3.1 %

LQDA stock opened at $15.38 on Monday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.82 and a beta of 0.16. Liquidia has a fifty-two week low of $5.71 and a fifty-two week high of $16.99. The business has a 50 day moving average price of $14.38 and a 200 day moving average price of $10.34.

Insider Activity

In other news, General Counsel Russell Schundler sold 8,653 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $136,890.46. Following the transaction, the general counsel now owns 488,087 shares of the company’s stock, valued at $7,721,536.34. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Roger Jeffs sold 28,583 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.82, for a total transaction of $452,183.06. Following the transaction, the chief executive officer now owns 835,345 shares of the company’s stock, valued at $13,215,157.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 8,653 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $136,890.46. Following the transaction, the general counsel now directly owns 488,087 shares in the company, valued at approximately $7,721,536.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,605 shares of company stock valued at $862,904. Company insiders own 31.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Fortitude Family Office LLC acquired a new position in Liquidia during the fourth quarter worth $26,000. UBS Group AG boosted its position in Liquidia by 134.0% during the second quarter. UBS Group AG now owns 7,948 shares of the company’s stock worth $35,000 after purchasing an additional 4,552 shares in the last quarter. Legal & General Group Plc purchased a new stake in Liquidia during the second quarter worth $38,000. BNP Paribas Arbitrage SA boosted its position in Liquidia by 42.8% during the second quarter. BNP Paribas Arbitrage SA now owns 10,682 shares of the company’s stock worth $47,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Liquidia by 101.3% during the second quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock worth $55,000 after purchasing an additional 3,524 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).